Daily oral pre-exposure prophylaxis (PrEP) is the use of antiretroviral drugs by HIV-negative
people to prevent HIV infection. WHO released new guidelines in 2015 recommending PrEP …

Recent research has demonstrated how antiretrovirals (ARVs) could be effective in the
prevention of sexually transmitted HIV. We review research on the acceptability of oral pre …

This study examined potential facilitators and barriers to pre-exposure prophylaxis (PrEP)
use and their association with PrEP acceptability and motivations for adherence among 184 …

Background The use of antiviral medications by HIV negative people to prevent acquisition
of HIV or pre-exposure prophylaxis (PrEP) has shown promising results in recent trials. To …

The use of antiretroviral medications in HIV-negative individuals as pre-exposure
prophylaxis (PrEP) is a promising approach to prevent HIV infection. Tenofovir disoproxil …

ABSTRACT HIV pre-exposure prophylaxis (PrEP) presents new opportunities for HIV
prevention. While women comprise approximately 20% of new HIV infections in the US …

Limited data exist regarding attitudes and acceptability of topical and oral HIV pre-exposure
prophylaxis (PrEP) among US black women. This investigation explored interest in HIV …

This working paper provides a detailed technical description of the THEMBISA model, an
integrated demographic and epidemiological model of the South African HIV/AIDS epidemic …

We aim to provide evidence-based guidance on best clinical practice in the provision,
monitoring and support of pre-exposure prophylaxis (PrEP) for the prevention of HIV …

This article examines how biomedicalisation is encountered, responded to and negotiated
within and in relation to new biomedical forms of HIV prevention. We draw on exploratory …